Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (81-90 of 432) with videos related to

Pageof 44
Sort By:
Vox Sanguinis|January 5, 2022
The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patientsAliénor Xhaard, Elsa Miekoutima, France Pirenne, et al.
Biochemical Pharmacology|July 12, 2008
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparisonSimone Boehrer, Lionel Adès, Lorenzo Galluzzi, et al.
British Journal of Haematology|July 22, 2014
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromesMikkael A Sekeres, Aristoteles Giagounidis, Hagop Kantarjian, et al.
Leukemia Research|May 14, 2016
Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndromeYoussoufa M Ousseine, Phyllis N Butow, Claire Julian-Reynier, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 17, 2019
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III TrialGuillermo Garcia-Manero, Antonio Almeida, Pierre Fenaux, et al.
Plos One|June 9, 2015
Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork ProteinsRoland Chanet, Guy Kienda, Amélie Heneman-Masurel, et al.
Leukemia & Lymphoma|July 16, 2005
Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patientsJérôme Cornillon, Abir Fawaz, Stéphane Depil, et al.
Blood|July 20, 2002
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentCatherine Roche-Lestienne, Valerie Soenen-Cornu, Nathalie Grardel-Duflos, et al.
British Journal of Haematology|December 22, 2022
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemiaNorman Salomao, Nabih Maslah, Anouk Giulianelli, et al.
Cell Cycle (Georgetown, Tex.)|July 22, 2008
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblastsClaire Fabre, Jennifer Grosjean, Maximilien Tailler, et al.
Pageof 44

Showing results (81-90 of 432) with videos related to

Sort By:
Pageof 44
Vox Sanguinis|January 5, 2022
The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patientsAliénor Xhaard, Elsa Miekoutima, France Pirenne, et al.
Biochemical Pharmacology|July 12, 2008
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparisonSimone Boehrer, Lionel Adès, Lorenzo Galluzzi, et al.
British Journal of Haematology|July 22, 2014
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromesMikkael A Sekeres, Aristoteles Giagounidis, Hagop Kantarjian, et al.
Leukemia Research|May 14, 2016
Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndromeYoussoufa M Ousseine, Phyllis N Butow, Claire Julian-Reynier, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 17, 2019
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III TrialGuillermo Garcia-Manero, Antonio Almeida, Pierre Fenaux, et al.
Plos One|June 9, 2015
Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork ProteinsRoland Chanet, Guy Kienda, Amélie Heneman-Masurel, et al.
Leukemia & Lymphoma|July 16, 2005
Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patientsJérôme Cornillon, Abir Fawaz, Stéphane Depil, et al.
Blood|July 20, 2002
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentCatherine Roche-Lestienne, Valerie Soenen-Cornu, Nathalie Grardel-Duflos, et al.
British Journal of Haematology|December 22, 2022
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemiaNorman Salomao, Nabih Maslah, Anouk Giulianelli, et al.
Cell Cycle (Georgetown, Tex.)|July 22, 2008
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblastsClaire Fabre, Jennifer Grosjean, Maximilien Tailler, et al.
Pageof 44